Literature DB >> 23085728

Association of circulating fibroblast growth factor-23 with renal phosphate excretion among hemodialysis patients with residual renal function.

Mengjing Wang1, Li You, Haiming Li, Yong Lin, Zhijie Zhang, Chuanming Hao, Jing Chen.   

Abstract

BACKGROUND AND OBJECTIVES: High serum levels of fibroblast growth factor-23 (FGF-23) are associated with mortality in patients with ESRD, but whether it still acts as a phosphaturic factor is unknown. This study aimed to explore the role of circulating FGF-23 on urinary phosphate excretion and phosphate balance in maintenance hemodialysis (MHD) patients with residual renal function (RRF). DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: There were 134 MHD patients enrolled in this cross-sectional study from June to July 2010. Demographics, laboratory data, and excretion capacity of phosphate were recorded. Multivariable linear regression was used to analyze the relationship of serum phosphate and the tubular reabsorption rate of phosphate with other factors.
RESULTS: The median age of the patients was 61.0 years and 47.8% were male. Thirty percent of the patients had high urinary output (>200 ml/d) accompanied by lower serum levels of phosphate, calcium, intact parathyroid hormone, and FGF-23 compared with those with low urine output (≤200 ml/d). The independent predictors of serum phosphate were normalized protein nitrogen appearance, intact parathyroid hormone, and FGF-23 in the low urine output group and female sex and GFR in the high urine output group. The tubular reabsorption rate of phosphate decreased to 50% of the normal level in patients with RRF. Elevated circulating FGF-23 was significantly associated with lower tubular phosphate reabsorption after adjusting for GFR.
CONCLUSIONS: RRF is associated with significant capacity to excrete phosphate in MHD patients and high levels of serum FGF-23 may promote phosphate excretion by remnant nephrons.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23085728      PMCID: PMC3531650          DOI: 10.2215/CJN.00230112

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  48 in total

1.  Nutritional management of dialysis patients: balancing among nutrient intake, dialysis dose, and nutritional status.

Authors:  Toshiyuki Nakao; Hiroshi Matsumoto; Tomonari Okada; Yoshie Kanazawa; Maki Yoshino; Yume Nagaoka; Fumihiro Takeguchi
Journal:  Am J Kidney Dis       Date:  2003-03       Impact factor: 8.860

2.  Klotho: a novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule.

Authors:  Ming Chang Hu; Mingjun Shi; Jianning Zhang; Johanne Pastor; Teruyo Nakatani; Beate Lanske; M Shawkat Razzaque; Kevin P Rosenblatt; Michel G Baum; Makoto Kuro-o; Orson W Moe
Journal:  FASEB J       Date:  2010-05-13       Impact factor: 5.191

Review 3.  Clinical benefit of preserving residual renal function in dialysis patients: an update for clinicians.

Authors:  Zachary Z Brener; Peter Kotanko; Stephan Thijssen; James F Winchester; Michael Bergman
Journal:  Am J Med Sci       Date:  2010-05       Impact factor: 2.378

4.  Role of residual renal function in phosphate control and anemia management in chronic hemodialysis patients.

Authors:  E Lars Penne; Neelke C van der Weerd; Muriel P C Grooteman; Albert H A Mazairac; Marinus A van den Dorpel; Menso J Nubé; Michiel L Bots; Renée Lévesque; Piet M ter Wee; Peter J Blankestijn
Journal:  Clin J Am Soc Nephrol       Date:  2010-10-28       Impact factor: 8.237

5.  Phosphate removal model: an observational study of low-flux dialyzers in conventional hemodialysis therapy.

Authors:  Mengjing Wang; Haiming Li; Huimin Liao; Yongfu Yu; Li You; Jianguo Zhu; Bihong Huang; Li Yuan; Chuanming Hao; Jing Chen
Journal:  Hemodial Int       Date:  2012-02-23       Impact factor: 1.812

Review 6.  Management of hyperphosphatemia.

Authors:  Martin K Kuhlmann
Journal:  Hemodial Int       Date:  2006-10       Impact factor: 1.812

Review 7.  Approach to renal tubular disorders.

Authors:  Arvind Bagga; Anurag Bajpai; Shina Menon
Journal:  Indian J Pediatr       Date:  2005-09       Impact factor: 1.967

8.  Serum levels of soluble secreted α-Klotho are decreased in the early stages of chronic kidney disease, making it a probable novel biomarker for early diagnosis.

Authors:  Yoshiko Shimamura; Kazu Hamada; Kosuke Inoue; Koji Ogata; Masayuki Ishihara; Toru Kagawa; Mari Inoue; Shimpei Fujimoto; Mika Ikebe; Kenji Yuasa; Shigeo Yamanaka; Teturo Sugiura; Yoshio Terada
Journal:  Clin Exp Nephrol       Date:  2012-03-29       Impact factor: 2.801

9.  Electrolyte disorders following oral sodium phosphate administration for bowel cleansing in elderly patients.

Authors:  Yichayaou Beloosesky; Josef Grinblat; Avraham Weiss; Boris Grosman; Uzi Gafter; Avry Chagnac
Journal:  Arch Intern Med       Date:  2003-04-14

10.  Metabolic acidosis is a potent stimulus for cellular inorganic phosphate generation in uraemia.

Authors:  A Bevington; D Brough; F E Baker; J Hattersley; J Walls
Journal:  Clin Sci (Lond)       Date:  1995-04       Impact factor: 6.124

View more
  9 in total

1.  Health care providers' support of patients' autonomy, phosphate medication adherence, race and gender in end stage renal disease.

Authors:  Ebele M Umeukeje; Joseph R Merighi; Teri Browne; Marcus Wild; Hafez Alsmaan; Kausik Umanath; Julia B Lewis; Kenneth A Wallston; Kerri L Cavanaugh
Journal:  J Behav Med       Date:  2016-05-11

Review 2.  Infrequent dialysis: a new paradigm for hemodialysis initiation.

Authors:  Connie M Rhee; Mark Unruh; Jing Chen; Csaba P Kovesdy; Phillip Zager; Kamyar Kalantar-Zadeh
Journal:  Semin Dial       Date:  2013-09-09       Impact factor: 3.455

Review 3.  Twice-weekly and incremental hemodialysis treatment for initiation of kidney replacement therapy.

Authors:  Kamyar Kalantar-Zadeh; Mark Unruh; Philip G Zager; Csaba P Kovesdy; Joanne M Bargman; Jing Chen; Suresh Sankarasubbaiyan; Gaurang Shah; Thomas Golper; Richard A Sherman; David S Goldfarb
Journal:  Am J Kidney Dis       Date:  2014-05-17       Impact factor: 8.860

4.  Association of Parameters of Mineral Bone Disorder with Mortality in Patients on Hemodialysis according to Level of Residual Kidney Function.

Authors:  Mengjing Wang; Yoshitsugu Obi; Elani Streja; Connie M Rhee; Wei Ling Lau; Jing Chen; Chuanming Hao; Takayuki Hamano; Csaba P Kovesdy; Kamyar Kalantar-Zadeh
Journal:  Clin J Am Soc Nephrol       Date:  2017-05-09       Impact factor: 8.237

5.  Short daily hemodialysis is associated with lower plasma FGF23 levels when compared with conventional hemodialysis.

Authors:  Joshua Zaritsky; Anjay Rastogi; George Fischmann; Jieshi Yan; Kenneth Kleinman; Georgina Chow; Barbara Gales; Isidro B Salusky; Katherine Wesseling-Perry
Journal:  Nephrol Dial Transplant       Date:  2013-09-05       Impact factor: 5.992

6.  Association of serum phosphorus variability with coronary artery calcification among hemodialysis patients.

Authors:  Mengjing Wang; Haiming Li; Li You; Xiaoling Yu; Min Zhang; Ruijiang Zhu; Chuanming Hao; Zhijie Zhang; Jing Chen
Journal:  PLoS One       Date:  2014-04-18       Impact factor: 3.240

7.  Metabolic and volume status evaluation of hemodialysis patients with and without residual renal function in the long interdialytic interval.

Authors:  Lenina Ludimila Sampaio de Almeida; Luís Henrique Bezerra Cavalanti Sette; Fernando Luiz Affonso Fonseca; Leila Silveira Vieira da Silva Bezerra; Francisco Hélio Oliveira Júnior; Ronaldo Roberto Bérgamo
Journal:  J Bras Nefrol       Date:  2019 Oct-Dec

8.  Significance of residual renal function for phosphate control in chronic hemodialysis patients.

Authors:  Harin Rhee; Ji Young Yang; Woo Jin Jung; Min Ji Shin; Byung Yoon Yang; Sang Heon Song; Ihm Soo Kwak; Eun Young Seong
Journal:  Kidney Res Clin Pract       Date:  2014-03-12

9.  Factors affecting the relationship between ionized and corrected calcium levels in peritoneal dialysis patients: a retrospective cross-sectional study.

Authors:  Masamitsu Morishita; Yukio Maruyama; Masatsugu Nakao; Nanae Matsuo; Yudo Tanno; Ichiro Ohkido; Masato Ikeda; Takashi Yokoo
Journal:  BMC Nephrol       Date:  2020-08-26       Impact factor: 2.388

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.